Facet Biotech Corporation

Pdl Biopharma, Inc.

Abbott Biotherapeutics Corp.

Harpoon Therapeutics, Inc.

Millennium Pharmaceuticals Limited

Cor Therapeutics, Inc.

Vanitha Ramakrishnan

David Powers

Vinay Bhaskar

Debbie Law

Dale E Johnson

Ursula Jeffry

Richard Murray

Daniel E Afar

Ingrid W Caras

Agustin De La Calle

Patrick A Baeuerle

Holger Wesche

Luke Evnin

Jeanmarie Guenot

Larry J Fretto

Maria Amelia Escobedo

David R Phillips

Yongke Zhang

Nathalie Lokker

Sun Ho

Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Trispecific binding proteins and methods of use

The present invention provides chimeric and humanized antibodies that specifically recognize &#x3b1;5&#x3b2;1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Chimeric and humanized antibodies to &#x3b1;5&#x3b2;1 integrin that modulate angiogenesis

The invention relates to the identification and generation of antibodies that bind to TMEFF2 proteins which are involved in cancer. Further, the invention provides for the use of these antibodies in the treatment of cancer.

Antibodies against cancer antigen TMEFF2 and uses thereof

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

The present invention provides methods for direct killing of cancer cells using anti-&#x3b1;5&#x3b2;1 antibodies. Generally, the method comprises contacting a cancer cell that expresses &#x3b1;5&#x3b2;1 on its surface with an anti-&#x3b1;5&#x3b2;1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-&#x3b1;5&#x3b2;1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Use of anti-&#x3b1;5&#x3b2;1 antibodies to inhibit cancer cell proliferation

Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.

Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer

Growing community of inventors

Belmont, CA, United States of America

Vanitha Ramakrishnan